维普期刊资源整合服务平台（V6.5）

84篇 您的检索式：作者名="Reckamp"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Non-small cell lung cancer in the elderly: defining treatment options显示文摘	Vora N Reckamp K L	2008	Semin Oncol2008，35，6：	1
2	Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin显示文摘	Reckamp KL Gardner BK Figlin RA	2008	J Thorac Oncol2008，3，2：	1
3	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non- Small-Cell Lung Cancer显示文摘	Brahmer J Reckamp KL Baas P	2015	N Engl J Med2015，373，2：	1
4	A phase 2 trial of dacomitinib ( PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor ) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib 显示文摘	Reckamp KL Giaccone G Camidge DR	2014	Cancer2014，120，8：	1
5	Akt inhibitors in clinical development for the treatment of cancer显示文摘	Pal SK Reckamp K Yu H		0，，：	1
6	Akt inhibitors in clinical development for the treatment of cancer 显示文摘	PAL K S RECKAMP K YU H	2010	Expert Opin Investig Drugs2010，19，11：	1
7	Targeted therapies for non- small cell lung cancer: an evolving landscape 显示文摘	PAL S K FIGLIN R A RECKAMP K	2010	Mol Cancer Ther2010，9，7：	1
8	Nivolumab versus Do- cetaxel in Advanced Squamous - Cell Non - Small - Cell Lung Cancer显示文摘	Brahmer J Reckamp KL Baas P	2015	N Engl J Med2015，373，2：	1
9	Non-small cell lung cancer in the elderly : defining treatment options 显示文摘	Vora N Reckamp KL	2008	Semin Oncol2008，35，：	1
10	Chemokines as therapeutic targets in renal cell carcinoma显示文摘	Reckamp KL Stricter RM Figlin RA	2008	Expert Rev Anticancer Ther2008，8，6：	1
11	The potential and rational for COX-2 inhibitors in lung cancer显示文摘	Krysan K Reckamp K L Sharma S	2006	Anticancer Agents Med Chem2006，6，3：	1
12	Non - small cell lung cancer In the eld- erly defining treatment options 显示文摘	Vora N Reckamp K L	2008	Sere in Oncol2008，35，：	1
13	Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer显示文摘	Mao JT Cui X Reckamp K	2005	Clin Lung Cancer2005，7，：	1
14	, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cane- er显示文摘	BrahmerJ Reckamp KL Baas P et ol	2015	N Engl J Med2015，373，：	1
15	Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer显示文摘The mutation-mediated overexpression of epidermal growth factor receptor tyrosine kinase(EGFR TK)and its activation play an important role in the cellular proliferation and epithelial tumorigenesis.A series of inhibitors targeting the intracellular tyrosine kinase(TK)domain of EGFR have been developed and applied to clinical practice.Although these inhibitors safely and effectively restrain tumor cell proliferation and prolong survival in some patients,acquired resistance ultimately arises.DNA mutations contribute to druginduced cancer-cell resistance.	Bing Liu Daniela Duenas Li Zheng Karen Reckamp Binghui Shen	2022	Protein & Cell2022，13，2：	1
16	The potential and rational for C)X-2 inhibitors in Lung cancer显示文摘	Krysan K Reckamp K L Sharma S	2006	Anticancer Agents Med Chert2006，6，3：	1
17	Stromal derived factor-1 (SDF-1/ CXCL12) and CXCR4 in renal cell carcinoma metastasis 显示文摘	Pan J Mestas J Burdiek M D Phillips R J Thomas G V Reckamp K	2006	Mol Cancer2006，5，：	1
18	Phase II trial of XLl84 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303)显示文摘	RECKAMP KL FRANKEL PF MACK PC	2014	J Clin Oneol2014，32，5：	1
19	Radiofrequency ablation in lung cancer:promising results in safety and efficacy显示文摘	Suh R Reckamp K Zeidler M	2005	Oncology2005，19，10：	1
20	A phaseⅠtrial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced nonsmall cell lung cancer显示文摘	Reckamp KL Krysan K Morrow JD Milne GL Newman RA Tucker C	2006	Clin Cancer Res2006，12，111：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示